2-(1H-咪唑-1-基)吡啶-3-胺 | 156489-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(1H-咪唑-1-基)吡啶-3-胺
• 英文名称: 2-(1H-imidazol-1-yl)pyridine-3-amine
• 英文别名: 2-(1H-imidazol-1-yl)pyridin-3-amine；2-imidazol-1-ylpyridin-3-amine
• CAS: 156489-93-9
• 化学式: C₈H₈N₄
• mdl: MFCD08668591
• 分子量: 160.178
• InChiKey: YZUACNPJPNGVMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  411.6±30.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-(1H-咪唑-1-基)吡啶-3-胺 反应 8.0h， 生成 N-((Z)-2-Imidazo[4,5-b]pyridin-3-yl-vinyl)-acetamide
  参考文献：
  名称：

  Lampe, John W.; Meo, Susan V. Di; Traina, Joseph A., Journal of Heterocyclic Chemistry, 1994, vol. 31, # 2, p. 287 - 292

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 26.0h， 生成 2-(1H-咪唑-1-基)吡啶-3-胺
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002

文献信息

• [EN] JAK1 SELECTIVE KINASE INHIBITOR<br/>[FR] INHIBITEUR SÉLECTIF DE KINASE JAK1
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2020211839A1

  公开（公告）日：2020-10-22

  Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).

  本文披露了式（I）的化合物及其药学上可接受的盐，这些化合物可用作JAK激酶抑制剂。还披露了包含一种或多种式（I）化合物的药物组合物，以及使用这些化合物或组合物治疗呼吸道疾病（例如哮喘或慢性阻塞性肺病）的方法。
• JAK1 SELECTIVE KINASE INHIBITOR
  申请人：DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

  公开号：EP3956322A1

  公开（公告）日：2022-02-23
• Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs
  作者：David D. Davey、P. W. Erhardt、E. H. Cantor、S. S. Greenberg、W. R. Ingebretsen、J. Wiggins

  DOI：10.1021/jm00113a002

  日期：1991.9

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.
• Lampe, John W.; Meo, Susan V. Di; Traina, Joseph A., Journal of Heterocyclic Chemistry, 1994, vol. 31, # 2, p. 287 - 292
  作者：Lampe, John W.、Meo, Susan V. Di、Traina, Joseph A.

  DOI：——

  日期：——